Ad
related to: fanapt vs risperdal cost insurance
Search results
Results From The WOW.Com Content Network
Iloperidone is indicated for the treatment of schizophrenia and mania or mixed episodes in bipolar I disorder. [2] [3] In a 2013 study in a comparison of 15 antipsychotic drugs in effectivity in treating schizophrenic symptoms, iloperidone demonstrated mild effectiveness — as effective as lurasidone, and 13 to 15% less effective than ziprasidone, chlorpromazine, and asenapine. [4]
In levying the penalty, the judge said the company’s off-label marketing campaign had demonstrated a “profit at all costs” mentality. (The verdict would ultimately be reduced by the state Supreme Court to $137 million.) Following the list of Risperdal troubles in the SEC filing was a new entry—J&J’s McNeil Consumer Healthcare division.
Now, in 2000, Excerpta began working on a plan to place dozens of Risperdal articles in medical journals. “Awareness articles” and “original reports,” of which a total of 39 were planned, would cost $22,000 each in fees, plus fees for the “authors.” Shorter pieces would be $9,000 each.
Another goal for the coming year was to “maximize and grow Risperdal’s market leadership in geriatrics and long term care.” Risperdal was already well ahead of Zyprexa in dementia market share, with 50 percent of the entire market. The goal was to boost that share still higher, to 57 percent, with sales of $302 million.
And the current wildfire losses come on top of last year’s Hurricane Helene, which cost private insurers between $6 billion and $11 billion, and Hurricane Milton, which produced insured losses ...
For example, if your coverage limit was up to $200,000, but the cost of rebuilding your home is $250,000, an extended replacement cost endorsement that covers up to 25 percent more than the policy ...
When a home insurance policy with a $300K dwelling limit already costs nearly $2,200 per year on average, it can be tempting to choose lower coverage limits to save money upfront. But, when you ...
On December 19, 2003—10 days after a Janssen salesman, making his bi-weekly visits, had dropped off another 1,592 sample doses for Austin Pledger’s doctor to try out on new patients—Janssen’s regulatory team had gone back to the FDA, in yet another effort to get children legally on to the Risperdal label.